Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab emtansine plus pertuzumab versus chemotherapy plus trastuzumab and pertuzumab in HER2-positive early breast cancer
2012-004879-38Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab emtansine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Locally assessed pathological complete response (pCR) rate. Started Mar 2014; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004879-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004879-38.